Evotec (EVO) Projected to Post Quarterly Earnings on Wednesday

Evotec (NASDAQ:EVO) is anticipated to issue its Q4 2025 resultson Wednesday, April 8th. Analysts expect the company to announce earnings of $0.1126 per share and revenue of $276.9370 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 6:00 AM ET.

Evotec Stock Performance

EVO stock opened at $2.59 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03. The firm has a 50 day simple moving average of $3.09 and a 200-day simple moving average of $3.33. Evotec has a twelve month low of $2.31 and a twelve month high of $4.80.

Institutional Trading of Evotec

Several institutional investors have recently added to or reduced their stakes in EVO. BNP Paribas Financial Markets raised its holdings in shares of Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE boosted its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the period. Marshall Wace LLP bought a new position in Evotec during the 4th quarter worth $40,000. XTX Topco Ltd acquired a new stake in Evotec in the second quarter worth $66,000. Finally, HRT Financial LP bought a new stake in Evotec in the fourth quarter valued at $72,000. Institutional investors own 5.81% of the company’s stock.

Wall Street Analysts Forecast Growth

EVO has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Berenberg Bank assumed coverage on shares of Evotec in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.